Kui-Jin Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kui-Jin Kim has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Ji-Won Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
17 shared publications - Se Hyun Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
17 shared publications - Jin Won Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
16 shared publications - Koung Jin Suh
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
16 shared publications - Keun-Wook Lee
Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
15 shared publications - Jee Hyun Kim
Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
14 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Topoisomerase assay data related to Figure 2E. A) The doubling time and Mid-log Phase time for five HER2+ gastric cell lines (NUGC4, SNU216, MKN7, OE19, and NCI-N87). B) Representative uncropped gel of pUC19 plasmid DNA (0.5μg) treated with increasing units of recombinant topoisomerase 1 (TOPO1; 0, 0.5, 1, 2, 4, and 8 Units) and with 1μg of cytosolic and nuclear protein fractions prepared from NUGC4, SNU216, MKN7, OE19, and NCI-N87 cells. C) Representative uncropped gel of pUC19 plasmid DNA (1μg) treated with increasing TOPO1 (0, 0.5, 1, 2, 4, and 8 Units) and incremental amounts of nuclear protein (0.1, 0.5, 1 μg) from OE19 and NCI-N87 cells. Gels are presented in both the original format and in black and white inverted format to facilitate visualization of DNA bands.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Topoisomerase assay data related to Figure 2E. A) The doubling time and Mid-log Phase time for five HER2+ gastric cell lines (NUGC4, SNU216, MKN7, OE19, and NCI-N87). B) Representative uncropped gel of pUC19 plasmid DNA (0.5μg) treated with increasing units of recombinant topoisomerase 1 (TOPO1; 0, 0.5, 1, 2, 4, and 8 Units) and with 1μg of cytosolic and nuclear protein fractions prepared from NUGC4, SNU216, MKN7, OE19, and NCI-N87 cells. C) Representative uncropped gel of pUC19 plasmid DNA (1μg) treated with increasing TOPO1 (0, 0.5, 1, 2, 4, and 8 Units) and incremental amounts of nuclear protein (0.1, 0.5, 1 μg) from OE19 and NCI-N87 cells. Gels are presented in both the original format and in black and white inverted format to facilitate visualization of DNA bands.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5A. Representative uncropped blots showing the expression of HER2 and HER3 in OE19 and NCI-N87 cells immunoprecipitated with anti-HER2 antibody. Input, IgG, and HER2 immunoprecipitates are shown in Figure 5A.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5A. Representative uncropped blots showing the expression of HER2 and HER3 in OE19 and NCI-N87 cells immunoprecipitated with anti-HER2 antibody. Input, IgG, and HER2 immunoprecipitates are shown in Figure 5A.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 2F. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and γ-H2ax in OE19, and NCI-N87 cells following incubation with T-DXd (0, 2, 20, and 200 ng/mL) for 48 and 72h. The corresponding Vinculin loading controls are shown in Figure 2F.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 2F. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and γ-H2ax in OE19, and NCI-N87 cells following incubation with T-DXd (0, 2, 20, and 200 ng/mL) for 48 and 72h. The corresponding Vinculin loading controls are shown in Figure 2F.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 4A. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and PARP in NCI-N87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 2, 20 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 3, 0 ng/mL T-DXd and 20 μg/mL pertuzumab; lane 4, 20 ng/mL T-DXd and 20 μg/mL pertuzumab. The corresponding Vinculin loading controls are shown in Figure 2F.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 4A. Representative uncropped blots showing the expression of p-CHK1 S345, CHK1, and PARP in NCI-N87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 2, 20 ng/mL T-DXd and 0 μg/mL pertuzumab; lane 3, 0 ng/mL T-DXd and 20 μg/mL pertuzumab; lane 4, 20 ng/mL T-DXd and 20 μg/mL pertuzumab. The corresponding Vinculin loading controls are shown in Figure 2F.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Immunofluorescence of HER2 in SNU216 and MKN7 cells. Representative images showing immunofluorescence labeling of HER2 (green) in SNU216 and MKN7 cells. Nuclei were counterstained by Hoechst (blue). Scale bars: 10 μm.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Immunofluorescence of HER2 in SNU216 and MKN7 cells. Representative images showing immunofluorescence labeling of HER2 (green) in SNU216 and MKN7 cells. Nuclei were counterstained by Hoechst (blue). Scale bars: 10 μm.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5E. Representative uncropped blots showing the expression of p-HER3, HER3, p-AKT S473, and AKT in OE19 and NCI-NB87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 2, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 3, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 0 nM NRG1; lane 4, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 5, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 6, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1; lane 7, 200 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1. The corresponding Vinculin loading controls are shown in Figure 2E.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5E. Representative uncropped blots showing the expression of p-HER3, HER3, p-AKT S473, and AKT in OE19 and NCI-NB87 cells for 48 h with the following treatments: lane 1, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 2, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 0 nM NRG1; lane 3, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 0 nM NRG1; lane 4, 0 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 5, 200 ng/mL T-DXd, 0 μg/mL pertuzumab, and 1.5 nM NRG1; lane 6, 0 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1; lane 7, 200 ng/mL T-DXd, 2 μg/mL pertuzumab, and 1.5 nM NRG1. The corresponding Vinculin loading controls are shown in Figure 2E.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5B. Representative uncropped blots showing the expression of NRG1 in OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 5B.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 5B. Representative uncropped blots showing the expression of NRG1 in OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 5B.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 1C. Representative uncropped blots showing the expression of p-EGFR, EGFR, p-HER2, HER2, p-HER3, HER3, p-HER4, HER4, and TOP1 in MKN1, AGS, KATOIII, NUGC3, SNU1, SNU601, NUGC4, SNU16, SNU216, MKN7, OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 1C.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
Uncropped western blot related to Figure 1C. Representative uncropped blots showing the expression of p-EGFR, EGFR, p-HER2, HER2, p-HER3, HER3, p-HER4, HER4, and TOP1 in MKN1, AGS, KATOIII, NUGC3, SNU1, SNU601, NUGC4, SNU16, SNU216, MKN7, OE19, and NCI-N87 cells. The corresponding Vinculin loading controls are shown in Figure 1C.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
For HER2-positive advanced gastric cancer, a recent major therapeutic advancement is the development of trastuzumab deruxtecan (T-DXd), a HER2-directed antibody–drug conjugate. In this disease, simultaneously targeting HER2 and HER3 pathways has the potential to be a promising therapeutic strategy. However, the therapeutic approach of combining T-DXd with pertuzumab, which disrupts HER2–HER3 heterodimerization, has not yet been explored in gastric cancer, making this study a pioneering effort. In vitro, T-DXd efficacy correlated with high levels of membrane HER2 expression. Among the 12 cell lines tested, two cell lines (NCI-N87 and OE19) confirmed as HER2 3+ by IHC showed the most effective proliferation inhibition by T-DXd. When comparing NCI-N87 and OE19, HER2–HER3 dimerization was found to be more abundant in NCI-N87, and combination treatment with pertuzumab and T-DXd showed synergy in cell growth inhibition in NCI-N87 but not in OE19. NRG1 stimulation attenuated the antiproliferative effect of T-DXd. This attenuation of T-DXd activity by NRG1 was partially reversed by the addition of pertuzumab in NCI-N87 but not in OE19. Notably, the combination of T-DXd and pertuzumab enhanced membrane HER2 internalization more effectively in NCI-N87 than in OE19. In vivo mouse experiments using NCI-N87 cells showed the combination treatment significantly suppressed tumor growth compared with either monotherapy. Taken together, our findings suggest that dual targeting of HER2 and HER3 with T-DXd and pertuzumab may improve therapeutic outcomes in HER2-positive gastric cancer, particularly in tumors enriched with HER2–HER3 heterodimers. These preclinical data provide strong rationale for clinical trials evaluating this combination strategy in HER2-positive gastric cancer.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Pertuzumab Enhances the Antitumor Activity of T-DXd in HER2-Positive Gastric Cancer Cells
For HER2-positive advanced gastric cancer, a recent major therapeutic advancement is the development of trastuzumab deruxtecan (T-DXd), a HER2-directed antibody–drug conjugate. In this disease, simultaneously targeting HER2 and HER3 pathways has the potential to be a promising therapeutic strategy. However, the therapeutic approach of combining T-DXd with pertuzumab, which disrupts HER2–HER3 heterodimerization, has not yet been explored in gastric cancer, making this study a pioneering effort. In vitro, T-DXd efficacy correlated with high levels of membrane HER2 expression. Among the 12 cell lines tested, two cell lines (NCI-N87 and OE19) confirmed as HER2 3+ by IHC showed the most effective proliferation inhibition by T-DXd. When comparing NCI-N87 and OE19, HER2–HER3 dimerization was found to be more abundant in NCI-N87, and combination treatment with pertuzumab and T-DXd showed synergy in cell growth inhibition in NCI-N87 but not in OE19. NRG1 stimulation attenuated the antiproliferative effect of T-DXd. This attenuation of T-DXd activity by NRG1 was partially reversed by the addition of pertuzumab in NCI-N87 but not in OE19. Notably, the combination of T-DXd and pertuzumab enhanced membrane HER2 internalization more effectively in NCI-N87 than in OE19. In vivo mouse experiments using NCI-N87 cells showed the combination treatment significantly suppressed tumor growth compared with either monotherapy. Taken together, our findings suggest that dual targeting of HER2 and HER3 with T-DXd and pertuzumab may improve therapeutic outcomes in HER2-positive gastric cancer, particularly in tumors enriched with HER2–HER3 heterodimers. These preclinical data provide strong rationale for clinical trials evaluating this combination strategy in HER2-positive gastric cancer.